Confusing leaflets put patients off medication, reports Cancer Research UK

7 August 2009

Patients could stop taking their medicine if the risks of possible side effects are not clearly explained, says a study published in the British Journal of Health Psychology, August 10.

Unclear medicine leaflets lead patients to overestimate the risk of side effects by up to 50 per cent ' and can influence their decision about whether to take prescribed medication. Researchers questioned 285 visitors to Cancer Research UK's patient information web site, CancerHelp.

They found that people interpreted the risk of having side effects differently, when percentages were used as in: '20% of patients will have side effects' or when words were used such as common, very common or uncommon. But they were much more likely to have an accurate understanding of the risks when they were described as 'one in five people may have side effects'.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical